The successes seen with CD19-directed CAR T-cells in preclinical models translated into robust clinical responses in relapsed/refractory pediatric B-ALL patients treated with the CD19-directed CAR T-cell product tisagenlecleucel (Kymriah)39,40. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.